Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial
Rationale. Accumulated evidence implicates sympathetic activation as inducing oxidative stress and systemic inflammation, which in turn lead to hypertension, endothelial dysfunction, and atherosclerosis in obstructive sleep apnea (OSA). Statins through their pleiotropic properties may modify inflamm...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/423120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551451140816896 |
|---|---|
| author | Marie Joyeux-Faure Renaud Tamisier Jean-Philippe Baguet Sonia Dias-Domingos Stephen Perrig Georges Leftheriotis Jean-Paul Janssens Wojciech Trzepizur Sandrine H. Launois Françoise Stanke-Labesque Patrick A. Lévy Frédéric Gagnadoux Jean-Louis Pepin |
| author_facet | Marie Joyeux-Faure Renaud Tamisier Jean-Philippe Baguet Sonia Dias-Domingos Stephen Perrig Georges Leftheriotis Jean-Paul Janssens Wojciech Trzepizur Sandrine H. Launois Françoise Stanke-Labesque Patrick A. Lévy Frédéric Gagnadoux Jean-Louis Pepin |
| author_sort | Marie Joyeux-Faure |
| collection | DOAJ |
| description | Rationale. Accumulated evidence implicates sympathetic activation as inducing oxidative stress and systemic inflammation, which in turn lead to hypertension, endothelial dysfunction, and atherosclerosis in obstructive sleep apnea (OSA). Statins through their pleiotropic properties may modify inflammation, lipid profile, and cardiovascular outcomes in OSA. Methods. This multicenter, randomized, double-blind study compared the effects of atorvastatin 40 mg/day versus placebo over 12 weeks on endothelial function (the primary endpoint) measured by peripheral arterial tone (PAT). Secondary endpoints included office blood pressure (BP), early carotid atherosclerosis, arterial stiffness measured by pulse wave velocity (PWV), and metabolic parameters. Results. 51 severe OSA patients were randomized. Key demographics for the study population were age 54 ± 11 years, 21.6% female, and BMI 28.5 ± 4.5 kg/m2. In intention to treat analysis, mean PAT difference between atorvastatin and placebo groups was 0.008 (−0.29; 0.28), P=0.979. Total and LDL cholesterol significantly improved with atorvastatin. Systolic BP significantly decreased with atorvastatin (mean difference: −6.34 mmHg (−12.68; −0.01), P=0.050) whereas carotid atherosclerosis and PWV were unchanged compared to the placebo group. Conclusion. In OSA patients, 3 months of atorvastatin neither improved endothelial function nor reduced early signs of atherosclerosis although it lowered blood pressure and improved lipid profile. This trial is registered with NCT00669695. |
| format | Article |
| id | doaj-art-33bb07f50d9c474a948bab2f58190c5d |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-33bb07f50d9c474a948bab2f58190c5d2025-02-03T06:01:21ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/423120423120Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled TrialMarie Joyeux-Faure0Renaud Tamisier1Jean-Philippe Baguet2Sonia Dias-Domingos3Stephen Perrig4Georges Leftheriotis5Jean-Paul Janssens6Wojciech Trzepizur7Sandrine H. Launois8Françoise Stanke-Labesque9Patrick A. Lévy10Frédéric Gagnadoux11Jean-Louis Pepin12University Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceCHU de Grenoble, Clinique de Cardiologie, Grenoble, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceLaboratoire du Sommeil, Service de Neuropsychiatrie, Hôpital Belle Idée, Genève, SwitzerlandLaboratoire d’explorations Fonctionnelles Vasculaires, CHU d’Angers, Angers, FranceService de Pneumologie, Hôpital Universitaire de Genève, Genève, SwitzerlandCHU d’Angers, Département de Pneumologie, Angers, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceCHU d’Angers, Département de Pneumologie, Angers, FranceUniversity Grenoble Alpes, HP2, Inserm U1042, Grenoble, FranceRationale. Accumulated evidence implicates sympathetic activation as inducing oxidative stress and systemic inflammation, which in turn lead to hypertension, endothelial dysfunction, and atherosclerosis in obstructive sleep apnea (OSA). Statins through their pleiotropic properties may modify inflammation, lipid profile, and cardiovascular outcomes in OSA. Methods. This multicenter, randomized, double-blind study compared the effects of atorvastatin 40 mg/day versus placebo over 12 weeks on endothelial function (the primary endpoint) measured by peripheral arterial tone (PAT). Secondary endpoints included office blood pressure (BP), early carotid atherosclerosis, arterial stiffness measured by pulse wave velocity (PWV), and metabolic parameters. Results. 51 severe OSA patients were randomized. Key demographics for the study population were age 54 ± 11 years, 21.6% female, and BMI 28.5 ± 4.5 kg/m2. In intention to treat analysis, mean PAT difference between atorvastatin and placebo groups was 0.008 (−0.29; 0.28), P=0.979. Total and LDL cholesterol significantly improved with atorvastatin. Systolic BP significantly decreased with atorvastatin (mean difference: −6.34 mmHg (−12.68; −0.01), P=0.050) whereas carotid atherosclerosis and PWV were unchanged compared to the placebo group. Conclusion. In OSA patients, 3 months of atorvastatin neither improved endothelial function nor reduced early signs of atherosclerosis although it lowered blood pressure and improved lipid profile. This trial is registered with NCT00669695.http://dx.doi.org/10.1155/2014/423120 |
| spellingShingle | Marie Joyeux-Faure Renaud Tamisier Jean-Philippe Baguet Sonia Dias-Domingos Stephen Perrig Georges Leftheriotis Jean-Paul Janssens Wojciech Trzepizur Sandrine H. Launois Françoise Stanke-Labesque Patrick A. Lévy Frédéric Gagnadoux Jean-Louis Pepin Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial Mediators of Inflammation |
| title | Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial |
| title_full | Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial |
| title_fullStr | Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial |
| title_full_unstemmed | Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial |
| title_short | Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial |
| title_sort | response to statin therapy in obstructive sleep apnea syndrome a multicenter randomized controlled trial |
| url | http://dx.doi.org/10.1155/2014/423120 |
| work_keys_str_mv | AT mariejoyeuxfaure responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT renaudtamisier responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT jeanphilippebaguet responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT soniadiasdomingos responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT stephenperrig responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT georgesleftheriotis responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT jeanpauljanssens responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT wojciechtrzepizur responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT sandrinehlaunois responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT francoisestankelabesque responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT patrickalevy responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT fredericgagnadoux responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial AT jeanlouispepin responsetostatintherapyinobstructivesleepapneasyndromeamulticenterrandomizedcontrolledtrial |